GLP-1 medications will likely expand beyond their current uses for diabetes or weight loss, according to money managers at Tema
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
Read Next
- Biden confronts Gaza, 2024 election weak spots in Morehouse speech
- Stocks may rise into the summer. These 3 risks could derail the rally.
- The biggest earnings heavy hitter reports this week, and so do Target and other retailers
- Currency Speculators raise Euro & US Dollar bets into positive levels :: InvestMacro
- The year of AI PCs
- Exclusive: XTX Markets sees 19% decline in 2023 UK Revenues to £2.0 billion
- Speculator bets led higher by Corn & Wheat :: InvestMacro
